Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Open-label, Single-arm Study to Assess the Safety and Efficacy of BPI-7711 Capsule in Patients With Metastatic or Recurrent Non-small Cell Lung Cancer With EGFR Mutation and T790M Mutation Positive.

NCT03812809 is registered in ClinicalTrials.gov with Beta Pharma Shanghai as lead sponsor.

NCT NCT03812809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03812809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Open-label, Single-arm Study to Assess the Safety and Efficacy of BPI-7711 Capsule in Patients With Metastatic or Recurrent Non-small Cell Lung Cancer With EGFR Mutation and T790M Mutation Positive.
Lead sponsor
Beta Pharma Shanghai
Phase
Phase 2
Overall status
Completed
Start date
July 5, 2019
Completion date
January 24, 2022
Enrollment
226 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc